BPTS News and Press, Biophytis SA From 04/20/22

Gainers: AlloVir (ALVR) +41%. Biophytis (BPTS) +22%. Clarus Therapeutics (CRXT) +22%. Healthcare Services (HCSG) +20%. BioSig Technologies (BSGM) +6%. Losers: Arcturus Therapeutics (ARCT) -22%. Diffusion Pharmaceuticals (DFFN) -13%. Seer (SEER) -7%. HTG Molecular...

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 19, 2022 / Biophytis SA ((NASDAQ:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with agi...

Gainers: Trevi Therapeutics (TRVI) +36%. Sunshine Biopharma (SBFM) +31%. IMAC Holdings (IMAC) +28%. Werewolf Therapeutics (HOWL) +25%. Ikena Oncology (IKNA) +22%. Losers: Aptinyx (APTX) -47%. Vapotherm (VAPO) -29%. Rite Aid (RAD) -23%. Biophytis (BPTS) -13%. Science 37 Holdings (SNC...

Aptinyx (APTX) -52% after reports results from Phase 2b study of NYX-2925 in painful diabetic peripheral neuropathy. Vapotherm (VAPO) -22% after withdraws FY22 guidance; sees Q1 revs below consensus. Rite Aid (RAD) -18% as Deutsche Bank slashes price target to $1. Bio...

Biophytis (NASDAQ:BPTS) has lost ~18% in the pre-market Thursday after the clinical-stage biotech highlighted the impact of COVID-19 on its ongoing clinical studies for the lead candidate Sarconeos (BIO101) in sarcopenia (SARA) and COVID-19 (COVA). At the end-of-treatment visit...

Biophytis press release (NASDAQ:BPTS): FY GAAP EPS of -€0.26. Cash and cash equivalents and short-term deposits included in other current financial assets as of December 31, 2021 were €23.9 million, a significant increase of €5.6 million compared to €18.3 million a...

Success of Nasdaq IPO in February 2021 €23.9M of available cash on December 31 2021 and new financing instruments for a total of €42M allowing financial visibility beyond mid 2023 Strong growth of operational expenses to €26.8M, mainly reflecting clinical prog...

Sarcopenia (SARA) : discussions engaged with FDA for the preparation of a Phase 2-3 program in sarcopenia, with the objective of having a First Patient In by end of H2 2022 COVID-19 (COVA): 237 patients enrolled - early termination of recruitment due to global drop of COVID-19 hospital...

Biophytis (NASDAQ:BPTS) said Tuesday it appointed Philippe Rousseau as CFO. Rousseau replaces Evelyne Nguyen, who is leaving BPTS to pursue other projects. Prior to joining BPTS, Rousseau was COO of Pherecydes Pharma, an antibacterial therapeutics development company. For further ...

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 5, 2022 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company specialized in the development of therapeutics that slow the degenerative processes associated with ag...